Paper41540504
miR-22-Galectin-1 as an integral signaling axis in regulating metabolism and immunity in HCC.
Hu Y and 10 others. Biomark Res, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. miR-22-Galectin-1 as an integral signaling axis in regulating metabolism and immunity in HCC. Papers, record 41540504. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41540504
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- miR-22-Galectin-1 as an integral signaling axis in regulating metabolism and immunity in HCC.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA093373 | NCI NIH HHS | United States | P30CA093373 | PubMed | NIH RePORTER |
| R01 CA222490 | NCI NIH HHS | United States | R01CA222490 | PubMed | NIH RePORTER |
| R01CA222490 | NIH HHS | United States | R01CA222490 | PubMed | NIH RePORTER |
References86
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27922690 | MicroRNA-152 inhibits tumor cell growth by directly targeting RTKN in hepatocellular carcinoma. | Oncol Rep | 2017 | https://conductscience.org/library/papers/27922690 | PubMed |
| 2 | 37254440 | Liver directed adeno-associated viral vectors to treat metabolic disease. | J Inherit Metab Dis | 2024 | https://conductscience.org/library/papers/37254440 | PubMed |
| 3 | 36703969 | Inhibition of galectins in cancer: Biological challenges for their clinical application. | Front Immunol | 2022 | https://conductscience.org/library/papers/36703969 | PubMed |
| 4 | 25175738 | All-trans retinoic acid regulates hepatic bile acid homeostasis. | Biochem Pharmacol | 2014 | https://conductscience.org/library/papers/25175738 | PubMed |
| 5 | 28055292 | Molecular control of Rab activity by GEFs, GAPs and GDI. | Small GTPases | 2018 | https://conductscience.org/library/papers/28055292 | PubMed |
| 6 | 38261802 | Targeting stroma and tumor, silencing galectin 1 treats orthotopic mouse hepatocellular carcinoma. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/38261802 | PubMed |
| 7 | 20943850 | Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. | Clin Chem | 2010 | https://conductscience.org/library/papers/20943850 | PubMed |
| 8 | 25042151 | OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis. | Eur J Cancer | 2014 | https://conductscience.org/library/papers/25042151 | PubMed |
| 9 | 37835594 | Mannose-Binding Lectin 2 as a Potential Therapeutic Target for Hepatocellular Carcinoma: Multi-Omics Analysis and Experimental Validation. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37835594 | PubMed |
| 10 | 35325185 | DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). | Nucleic Acids Res | 2022 | https://conductscience.org/library/papers/35325185 | PubMed |
| 11 | 24496460 | Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. | Br J Cancer | 2014 | https://conductscience.org/library/papers/24496460 | PubMed |
| 12 | 21880716 | Synergistic induction of galectin-1 by CCAAT/enhancer binding protein alpha and hypoxia-inducible factor 1alpha and its role in differentiation of acute myeloid leukemic cells. | J Biol Chem | 2011 | https://conductscience.org/library/papers/21880716 | PubMed |
| 13 | 33005474 | MiR-22 as a metabolic silencer and liver tumor suppressor. | Liver Res | 2020 | https://conductscience.org/library/papers/33005474 | PubMed |
| 14 | 29440144 | SPON2 Promotes M1-like Macrophage Recruitment and Inhibits Hepatocellular Carcinoma Metastasis by Distinct Integrin-Rho GTPase-Hippo Pathways. | Cancer Res | 2018 | https://conductscience.org/library/papers/29440144 | PubMed |
| 15 | 37609633 | DoSurvive: A webtool for investigating the prognostic power of a single or combined cancer biomarker. | iScience | 2023 | https://conductscience.org/library/papers/37609633 | PubMed |
| 16 | 30252536 | RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells. | FASEB J | 2019 | https://conductscience.org/library/papers/30252536 | PubMed |
| 17 | 7890630 | Galectin-1, a beta-galactoside-binding lectin in Chinese hamster ovary cells. I. Physical and chemical characterization. | J Biol Chem | 1995 | https://conductscience.org/library/papers/7890630 | PubMed |
| 18 | 28892150 | Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation. | J Pathol | 2017 | https://conductscience.org/library/papers/28892150 | PubMed |
| 19 | 17043243 | Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/17043243 | PubMed |
| 20 | 31160556 | Pseudogene RACGAP1P activates RACGAP1/Rho/ERK signalling axis as a competing endogenous RNA to promote hepatocellular carcinoma early recurrence. | Cell Death Dis | 2019 | https://conductscience.org/library/papers/31160556 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42529129 | Galectins at the crossroads of tumor immunity, metabolism, and metastasis: mechanisms, therapeutic resistance, and translational opportunities. | Front Immunol | 2026 | https://conductscience.org/library/papers/42529129 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41540504
GET https://conductscience.org/api/papers/v1/41540504/references?page=2